Dignitana AB Publishes Q1 2021 Interim Report

Reopening and reimbursement progress

 

Financial highlights Q1 2021

  • Net sales amounted to 13,2 MSEK (11,4), an increase of 16 percent over the same period 2020

  • Operating result amounted to -7,1 MSEK (-12,5)
  • Net result after financial items amounted to -7,7 MSEK (-12,8)
  • Earnings per share was -0,12 SEK (-0,23)
  • Cash Balance amounted to 44,4 MSEK (8,8)
  • Average Daily Treatment Revenue (ADTR)* was 130 TSEK (118), an increase of 10 percent over the same period in 2020

Significant events during the period

  • The Extraordinary General Meeting on January 11 approved the Board of Directors’ resolution on the directed issue of shares made on 22 December 2020

Business highlights during the period

  • Dignitana expanded agreement with GenesisCare to include United States

  • Mammazentrum Hamburg selected DigniCap Delta to provide upgraded scalp cooling therapy
  • Dignitana announced the specific CPT codes for DigniCap which will be available to patients on 1 July 2021
  • The Company highlighted new clinical guidelines from leading oncology organizations around the world which recommend scalp cooling
  • The Company has repaid in full the 20 MSEK unsecured loan received from Adma Förvaltnings AB in the third period of 2020

Significant events after the period

  • Dignitana published the 2020 Annual Report

Business highlights after the period

  • Dignitana-backed insurance legislation cleared Texas House committee

 

Key Figures

DIGNITANA GROUP

Q1 2021

Q1 2020

Full Year 2020

Net sales, TSEK  13 165  11 393  46 629
Total revenues, TSEK  14 157  12 478  49 956
Net profit after financial items, TSEK -7 664 -12 755 -52 963
Cash and bank balances, TSEK 44 366    8 768  78 770
Earnings per share before and after dilution, SEK -0,12 -0,23 -0,96
Average Daily Treatment Revenue*, TSEK 130 118 120

* ADTR includes pay-per-treatment revenue from patients and facilities. Does not include lease revenue or disposable sales.

All financial reports are available at www.dignitana.com/investor-relations/financial-reports/

 


 

This disclosure contains information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 20-05-2021 08:25 CET.

For More Information Contact 

Melissa Bourestom, VP Corporate Communications,  melissa.bourestom@dignitana.com  +1 469-518-5031

About Dignitana

Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001.  Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and operations based in Dallas, Texas in the United States.  Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Certified Adviser is Redeye AB +46 8 121 576 90, certifiedadviser@redeye.se. Learn more at www.dignitana.se or www.dignicap.com

Tags:

Subscribe

Quotes

Our relentless commitment to patient success is the driving force behind everything we do. By maintaining this focus and making scalp cooling a standard of care, I am confident that we will meet our long-term financial goals.
William Cronin, CEO Dignitana AB